Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03538756 · ClinicalTrials.gov registry record · NA
walk2Wellness: Long-term Effects of Walkasins® Wearable Sensory Prosthesis
A NA study, sponsored by RxFunction.
- Completed
- Registry status
- NA
- Development phase
- 69
- Enrollment target
NCT03538756: Completed NA study, sponsored by RxFunction.
NCT03538756 is a NA study that has completed, run by RxFunction. The registered enrollment target is 69 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03538756, a NA study, has completed, sponsored by RxFunction.
- COMPLETED
- Registry status
- NA
- Development phase
- 69 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the long-term effects of Walkasins® use on clinical and subject-reported outcomes of balance and gait function, quality of life, physical activity/participation, pain, and medication use in persons with peripheral neuropathy who experience balance problems.
Primary Outcome
The Functional Gait Assessment (FGA) is a 10-item scale that measures postural stability while individuals perform walking tasks that are scored from 0 to 3 (3 = normal, 2 = mild impairment, 1 = moderate impairment, 0 = severe impairment). Scores range from a minimum of 0 to a maximum of 30. Higher scores indicate better postural stability. (Participants scoring 23 or higher on the baseline FGA were not included in this study because their peripheral neuropathy was not yet affecting their gait/b
Interventions
- DEVICE Walkasins
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2018-10-22 |
| Est. Completion | 2021-12-31 |
| Phase | NA |
What the finished NCT03538756 record still lists
NCT03538756 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 69 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Walkasins is the first listed.
NCT03538756 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03538756 about?
NCT03538756 is a clinical study titled "walk2Wellness: Long-term Effects of Walkasins® Wearable Sensory Prosthesis". The purpose of this study is to investigate the long-term effects of Walkasins® use on clinical and subject-reported outcomes of balance and gait function, quality of life, physical activity/participation, pain, and medication use in persons with peripheral neuropathy who experience balance problems...
What is the current status of trial NCT03538756?
This trial is currently completed. It is a NA study. The enrollment target is 69 participants. The study started on 2018-10-22. Estimated completion is 2021-12-31.
What interventions are being tested in trial NCT03538756?
The interventions under investigation include: Walkasins (DEVICE).
Who is sponsoring clinical trial NCT03538756?
This trial is sponsored by RxFunction, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03538756's enrollment target sits among peer trials
69 1133rd of 2000 higher than 868 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04020575 · 69 participants · Phase 1
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
- NCT04163614 · 69 participants · NA
Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients
- NCT04164641 · 69 participants · NA
Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic Gait Correction in Reducing Diabetic Foot Ulceration Or Subsequent Amputation in Patients With a History of a Diabetic Foot Ulceration
- NCT04493372 · 69 participants · NA
Deciphering Preserved Autonomic Function After Spinal Cord Injury
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI